Remaining on treatment, responding and becoming seizure-free were related but separately counted outcomes.
The retrospective adjunctive-clobazam study included 146 children with drug-resistant epilepsy. Retention was 87.67% at six months and 81.51% at twelve months. Response rates were approximately 59% and 62%, using evaluable denominators of 139 and 133; seizure-free rates were approximately 37% and 35%. Lower baseline seizure frequency was associated with response, and genetic subgroups showed different patterns.
All patients were receiving multiple antiseizure medicines, with other treatments changing during follow-up. Seizure counts depended on family reports and medical records. The study lacked a parallel control, and small genotype subgroups do not establish reliable personalized predictions. Retention can reflect efficacy, tolerability, access and clinical decisions together.
When assessing treatment history, specify the denominator and the definition of response. A retention percentage should not be described as the seizure-control rate, and an apparent subgroup advantage should retain its exploratory context. The paper supports a real-world description of adjunctive use. It cannot isolate clobazam’s contribution to one child’s improvement or establish the reason for discontinuation without the actual seizure timeline, co-medication changes and adverse-effect observations.
Source: PMC12701652, supplied full-text paper. Findings are paraphrased; forensic implications are an interpretation.
Related: Recurrent Hypothermia Stopped After Clobazam Withdrawal in an Adult Case.